Literature DB >> 15352034

The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis.

Chris Braumann1, Wolfgang Henke, Christoph A Jacobi, Wolfgang Dubiel.   

Abstract

Taurolidine has been successfully used as a disinfectant and to prevent the spreading and growth of tumor cells after surgical excision. However, the underlying mechanisms regarding its effects remain obscure. Here, we show that taurolidine treatment reduces endogenous levels of IkappaBalpha, p105, c-Jun, p53 and p27 in a dose-dependent manner in colon adenocarcinoma cells, which can be in part due to massive cell death. Because expression of tested proteins was affected by taurolidine, its influence on protein expression was studied. In the coupled transcription/translation system, taurolidine inhibited c-Jun expression with an IC50 value of 1.4 mM. There was no or little effect on transcription. In contrast, translation of c-Jun or p53 mRNA was completely inhibited by taurolidine. To determine which step of translation was affected, prominent complexes occurring in the course of translation were analyzed by density gradient centrifugation. In the presence of taurolidine, no preinitiation translation complex was assembled. Taurolidine also suppressed protein expression in bacteria. Based on our data, we conclude that taurolidine blocks a fundamental early phase of translation, which might explain its effects as a disinfectant and inhibitor of tumor growth. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15352034     DOI: 10.1002/ijc.20393

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines.

Authors:  Ansgar M Chromik; Adrien Daigeler; Daniel Bulut; Annegret Flier; Christina May; Kamran Harati; Jan Roschinsky; Dominique Sülberg; Peter R Ritter; Ulrich Mittelkötter; Stephan A Hahn; Waldemar Uhl
Journal:  J Exp Clin Cancer Res       Date:  2010-03-07

2.  The Antiseptic and Antineoplastic Agent Taurolidine Modulates Key Leukocyte Functions.

Authors:  Yannick Wouters; Gina R H Mennen; René H M Te Morsche; Hennie M J Roelofs; Geert J A Wanten
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

3.  Oral administration of the anti-proliferative substance taurolidine has no impact on dextran sulfate sodium induced colitis-associated carcinogenesis in mice.

Authors:  Ansgar Michael Chromik; Sebastian Huss; Hayssam Osseili; Adrien Daigeler; Sabine Kersting; Dominique Sülberg; Ulrich Mittelkötter; Thomas Herdegen; Waldemar Uhl; Annette M Müller
Journal:  J Carcinog       Date:  2010-04-16

4.  Evaluation of the safety and efficacy of TRAIL and taurolidine use on human fibrosarcoma xenografts in vivo.

Authors:  Kamran Harati; Sabine Emmelmann; Björn Behr; Ole Goertz; Tobias Hirsch; Nicolai Kapalschinski; Jonas Kolbenschlag; Ingo Stricker; Andrea Tannapfel; Marcus Lehnhardt; Adrien Daigeler
Journal:  Oncol Lett       Date:  2016-01-15       Impact factor: 2.967

5.  Gene expression analysis of cell death induction by taurolidine in different malignant cell lines.

Authors:  Ansgar M Chromik; Stephan A Hahn; Adrien Daigeler; Annegret Flier; Daniel Bulut; Christina May; Kamran Harati; Jan Roschinsky; Dominique Sülberg; Dirk Weyhe; Ulrich Mittelkötter; Waldemar Uhl
Journal:  BMC Cancer       Date:  2010-10-30       Impact factor: 4.430

6.  Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case.

Authors:  Chris Braumann; Goetz Winkler; Patrick Rogalla; Charalambos Menenakos; Christoph A Jacobi
Journal:  World J Surg Oncol       Date:  2006-06-24       Impact factor: 2.754

7.  Taurolidine reduces the tumor stimulating cytokine interleukin-1beta in patients with resectable gastrointestinal cancer: a multicentre prospective randomized trial.

Authors:  Chris Braumann; Carsten N Gutt; Johannes Scheele; Charalambos Menenakos; Wilhelm Willems; Joachim M Mueller; Christoph A Jacobi
Journal:  World J Surg Oncol       Date:  2009-03-23       Impact factor: 2.754

8.  TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma.

Authors:  Adrien Daigeler; Christina Brenzel; Daniel Bulut; Anne Geisler; Christoph Hilgert; Marcus Lehnhardt; Hans U Steinau; Annegret Flier; Lars Steinstraesser; Ludger Klein-Hitpass; Ulrich Mittelkötter; Waldemar Uhl; Ansgar M Chromik
Journal:  J Exp Clin Cancer Res       Date:  2008-12-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.